<a href="https://www.ddregpharma.com/what-is-a-new-drug-application">New Drug Application</a> (ANDA), any post-approval change to a drug product such as modifications to packaging, labeling, excipients, or physical appearance requires a formal submission to the FDA, classified as either CBE-0, CBE-30, or a Prior Approval Supplement (PAS). The FDA reviews each category based on the risk level of the proposed change. All three submission types must include: a description of the change and its rationale, and supporting technical data such as stability reports, comparative analytical data, and quality standards. For all three types, the FDA retains the authority to request additional information. CBE-0, CBE-30, and PAS are formal regulatory mechanisms that ensure the FDA is properly informed of post-market changes and that a drug's safety and quality are continuously monitored after market entry. <h2>What are the Differences Between CBE-0, CBE-30, and PAS?</h2> <h2>CBE-0: Changes Being Effected (Level 1 - Minor Changes)</h2> <ul><li>Applies to minor changes such as: minor editorial corrections to labeling, minor equipment changes that do not affect the manufacturing process, or other low-risk administrative modifications. </li><li>The change may be implemented immediately upon submission receipt at FDA; prior approval is not required. </li><li>These changes do not affect the safety, efficacy, bioavailability, or quality of the drug product, and carry no risk of unexpected adverse effects.</li></ul> <h2>CBE-30: Changes Being Effected in 30 Days (Level 2 - Moderate Changes)</h2> <ul><li>Applies to moderate changes such as: changes to primary packaging components, replacement of an excipient with a comparable alternative in a moderate amount, or increases in batch size within approved limits. </li><li>The change may be implemented 30 days after the supplement is received at FDA, provided no objection is raised. </li><li>These changes do not affect the safety, efficacy, bioavailability, or quality of the drug product, and carry no risk of unexpected adverse effects.</li></ul> <h2>PAS: Prior Approval Supplement (Major Changes)</h2> <ul><li>Applies to major changes such as: modifications to the drug formulation, addition of a new active pharmaceutical ingredient (API), changes to the route of drug administration, or other changes that could significantly alter the product. </li><li>The change may only be implemented after the FDA completes its review and formally grants approval. </li><li>These changes may affect the safety, bioavailability, therapeutic efficacy, or pharmacokinetic profile of the drug product. </li><li>Processing time is typically 10 months under GDUFA performance goals for standard ANDA submissions.</li></ul> <h3>How CBE-0, CBE-30, and PAS Support Regulatory Oversight?</h3> This three-tier classification system enables the <a href="https://www.ddregpharma.com/what-is-the-united-states-food-and-drug-administration">FDA</a> to manage risk proportionally, without creating unnecessary delays in drug availability: <ul><li>CBE-0 - Low-risk changes with immediate implementation. </li><li>CBE-30 - Moderate-risk changes with a 30-day review window. </li><li>PAS - Major, high-risk changes requiring full FDA review and approval.</li></ul> By providing faster pathways for lower-risk modifications, the system minimizes the risk of drug shortages while maintaining rigorous oversight. It encourages pharmaceutical companies to adopt modern quality and manufacturing practices, allows the FDA to monitor all post-approval modifications, and enables the agency to intervene if unexpected risks arise at any stage. <h3>Required Documentation Summary</h3> <table> <thead> <tr> <td><div> Documents </div></td> <td><div> CBE-0 </div></td> <td><div> CBE-30 </div></td> <td><div> PAS </div></td> </tr> </thead> <tbody><tr> <td><div> FDA 356h Form </div></td> <td><div> Required </div></td> <td><div> Required </div></td> <td><div> Required </div></td> </tr> <tr> <td><div> Cover Letter </div></td> <td><div> Must state: Special Supplement – CBE-0 </div></td> <td><div> Must state: Special Supplement – CBE-30 </div></td> <td><div> Must state: Prior Approval Supplement </div></td> </tr> <tr> <td><div> Comparative Data </div></td> <td><div> Comparative analytical or dissolution data demonstrating no significant change </div></td> <td><div> Summary of analytical data </div></td> <td><div> Full batch analysis and validation </div></td> </tr> <tr> <td><div> Change Summary </div></td> <td><div> Narrative and rationale </div></td> <td><div> Narrative and rationale </div></td> <td><div> Detailed narrative and rationale </div></td> </tr> <tr> <td><div> Labeling </div></td> <td><div> Marked-up labeling </div></td> <td><div> Marked-up labeling </div></td> <td><div> Final printed labeling </div></td> </tr> <tr> <td><div> Batch Records </div></td> <td><div> Updated master record </div></td> <td><div> Master production record </div></td> <td><div> Executed and master production record </div></td> </tr> <tr> <td><div> Site Details </div></td> <td><div> Facility details </div></td> <td><div> Facility details </div></td> <td><div> Full facility details </div></td> </tr> <tr> <td><div> Implementation </div></td> <td><div> Immediately upon submission </div></td> <td><div> 30 days after submission </div></td> <td><div> Only after FDA approval </div></td> </tr> </tbody></table> DDReg Capabilities DDReg offers a wide range of global <a href="https://www.ddregpharma.com/solutions/regulatory-affairs">regulatory affairs services</a> tailored to country-specific requirements. Our experts support clients through every phase from initial submission to post-market surveillance ensuring alignment with the current standards of regulatory authorities including FDA, EMA, TGA, MHRA, and SFDA. Partner with DDReg to accelerate your product's entry into worldwide markets.

Learn the differences between CBE-0, CBE-30, and PAS submissions, FDA supplement types for post-approval drug changes and regulatory compliance.

What Are CBE-0, CBE-30, and PAS Submissions?